This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Zoetis Inc. came into existence following Pfizer’s decision to spin off its animal health business. he company is a leader in the discovery, development, manufacture and commercialization of animal health medicines, vaccines and diagnostic products with a focus on both livestock and companion animals. Zoetis has a diversified business, which caters to eight core species — cattle, swine, poultry, fish and sheep (collectively, livestock) and dogs, cats and horses (collectively, companion animals).
Zacks Earnings ESP: A Better Way to Find Earnings Surprises for Medical
by Zacks Equity Research
Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.
Zoetis (ZTS) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Zoetis (ZTS) is set to report impressive earnings and revenues and provide an update on its pipeline when it releases second-quarter 2022 results.
Zoetis (ZTS) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Zoetis (ZTS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
ASRT vs. ZTS: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
ASRT vs. ZTS: Which Stock Is the Better Value Option?
Why Zoetis (ZTS) Could Beat Earnings Estimates Again
by Zacks Equity Research
Zoetis (ZTS) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Aurinia (AUPH) Moves 13.3% Higher: Will This Strength Last?
by Zacks Equity Research
Aurinia (AUPH) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
ASRT or ZTS: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
ASRT vs. ZTS: Which Stock Is the Better Value Option?
ASRT vs. ZTS: Which Stock Is the Better Value Option?
by Zacks Equity Research
ASRT vs. ZTS: Which Stock Is the Better Value Option?
ASRT vs. ZTS: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
ASRT vs. ZTS: Which Stock Is the Better Value Option?
Zoetis' (ZTS) Q1 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Zoetis' (ZTS) earnings and revenues trump estimates in the first quarter of 2022.
Zoetis (ZTS) Tops Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Zoetis (ZTS) delivered earnings and revenue surprises of 8.20% and 0.88%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Drug/Biotech Stocks Q1 Earnings Due on May 5: VRTX, ZTS & More
by Zacks Equity Research
Let's look at the five biotech/drug companies, slated to release quarterly results on May 5.
Is a Beat in Store for Zoetis (ZTS) This Earnings Season?
by Zacks Equity Research
Zoetis (ZTS) is set to report earnings and revenue figures and provide updates on its pipeline when it releases first-quarter 2022 results.
Zoetis (ZTS) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release
by Zacks Equity Research
Zoetis (ZTS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Tenet Healthcare (THC) Q1 Earnings Beat Mark, Surge Y/Y
by Zacks Equity Research
Tenet Healthcare (THC) Q1 earnings gain from a healthy revenue stream, reduced expenses and operational efficiency.
Why the Earnings Surprise Streak Could Continue for Zoetis (ZTS)
by Zacks Equity Research
Zoetis (ZTS) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
The Zacks Analyst Blog Highlights PayPal Holdings, Zoetis, CSX, Northrop Grumman, and The Kraft Heinz
by Zacks Equity Research
PayPal Holdings, Zoetis, CSX, Northrop Grumman, and The Kraft Heinz are part of top Analyst Blog.
Top Analyst Reports for PayPal, Zoetis & CSX
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including PayPal Holdings, Inc. (PYPL), Zoetis Inc. (ZTS), and CSX Corporation (CSX).
COLL or ZTS: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
COLL vs. ZTS: Which Stock Is the Better Value Option?
COLL or ZTS: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
COLL vs. ZTS: Which Stock Is the Better Value Option?
Why Is Zoetis (ZTS) Down 1.6% Since Last Earnings Report?
by Zacks Equity Research
Zoetis (ZTS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
COLL or ZTS: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
COLL vs. ZTS: Which Stock Is the Better Value Option?
Russia-Ukraine Tensions Escalate: 3 ETFs to Buy
by Neena Mishra
Russian aggression against Ukraine has sent commodities and gold higher
Company News for Feb 16, 2022
by Zacks Equity Research
Companies In The News Are: MAR, ZTS, TRP, ANET.
Zoetis' (ZTS) Q4 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Zoetis' (ZTS) earnings and revenues beat estimates for the fourth quarter of 2021.